Curtis Chen, PA
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.1%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Galderma Laboratories, L.p. at 26.4% of the total. 2025 is the largest year on record at $55,457, more than ten times the $174 reported in 2022. Among medical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 508 payments — averaging $135.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Galderma Laboratories, L.p.$18K
- Arcutis Biotherapeutics, Inc.$16K
- Organon$10K
- Kowa Pharmaceuticals America, Inc.$8K
- Dermavant Sciences, Inc.$4K
- LEO Pharma Inc.$2K
- plus $11K from 21 others
What the payments were for
- Consulting fees$18,77827%
- Speaking & faculty fees$24,15035%
- Travel & lodging$11,61017%
- Food & beverage$13,98720%
- Education$2480%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Galderma Laboratories, L.p. | 50 | $18,149 |
| Arcutis Biotherapeutics, Inc. | 57 | $16,302 |
| Organon | 17 | $10,000 |
| Kowa Pharmaceuticals America, Inc. | 16 | $7,632 |
| Dermavant Sciences, Inc. | 82 | $3,603 |
| LEO Pharma Inc. | 49 | $2,278 |
| Incyte Corporation | 29 | $2,159 |
| AbbVie | 37 | $1,972 |
| UCB, Inc. | 40 | $1,420 |
| Mayne Pharma Commercial LLC | 1 | $1,000 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 17 | $967 |
| Johnson & Johnson | 21 | $835 |
| Pfizer | 16 | $512 |
| Sun Pharmaceutical Industries Inc. | 19 | $402 |
| Regeneron Healthcare Solutions, Inc. | 15 | $337 |
| Novartis | 8 | $235 |
| E.r. Squibb & Sons, L.L.C. | 9 | $207 |
| Sanofi | 7 | $176 |
| Journey Medical Corporation | 3 | $128 |
| Botanix SB Inc | 1 | $126 |
| Lilly USA, LLC | 4 | $93 |
| Helsinn Therapeutics (U.S.), Inc. | 3 | $76 |
| Amgen | 2 | $66 |
| Boehringer Ingelheim | 2 | $46 |
| Cipher Pharmaceuticals US LLC | 1 | $20 |
| Regeneron | 1 | $17 |
| Phadia US Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$68,772 in reported general payments places this provider in the 95th percentile of 2,395 medical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpzeluraRuxolitinib Phosphate | 235 | $475,476 |
| VtamaTapinarof | 270 | $368,427 |
| Dupixent PenDupilumab | 94 | $336,345 |
| JubliaEfinaconazole | 166 | $210,455 |
| ZoryveRoflumilast | 150 | $125,388 |
| AdbryTralokinumab-Ldrm | 18 | $65,298 |
| ErtaczoSertaconazole Nitrate | 56 | $52,155 |
| CabtreoAdapalene/Benzoyl/Clindamycin | 55 | $48,827 |
| Tacrolimus | 128 | $36,478 |
| ArazloTazarotene | 35 | $17,521 |
| DuobriiHalobetasol Propion/Tazarotene | 16 | $15,598 |
| Pimecrolimus | 32 | $15,026 |
| CrotanCrotamiton | 16 | $14,006 |
| Clindamycin Phosphate | 214 | $13,502 |
| Ammonium Lactate | 642 | $12,623 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationOpzelura | $2,159 | $475,476235 claims |
| Dermavant Sciences, Inc.Vtama | $3,603 | $368,427270 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia, Cabtreo, Arazlo, Duobrii | $967 | $292,400272 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $16,302 | $125,388150 claims |
| LEO Pharma Inc.Adbry | $2,278 | $65,29818 claims |
| PfizerEucrisa | $512 | $11,86915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,395 medical providers in New York.
Other medical in Bronx
- Nicholas SolarinoBronx$46K
- Moises AcevedoBronx$36K
- Geraldine JosephBronx$16K
- Lusi HartBronx$16K
- Rebecca EllwoodAlbany$565K
- Denisse SerranoCortlandt Manor$255K
- Michele Kissous-HuntNew York$246K
- Laura MaroldoNew York$126K
- Carl ClarkeBrooklyn$116K
- Maureen ThyneNew York$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.